{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:04:19Z","timestamp":1790035459891,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","award":["ESR-18-13635"],"award-info":[{"award-number":["ESR-18-13635"]}],"id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejca.2023.113373","type":"journal-article","created":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T15:48:14Z","timestamp":1697989694000},"page":"113373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-281X","authenticated-orcid":false,"given":"Tadaaki","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideharu","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5026-8078","authenticated-orcid":false,"given":"Hiroshi","family":"Gyotoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0643-0696","authenticated-orcid":false,"given":"Takeshi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-6981","authenticated-orcid":false,"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-1838","authenticated-orcid":false,"given":"Kenji","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Kiyomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-7767","authenticated-orcid":false,"given":"Junji","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-8960","authenticated-orcid":false,"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113373_bib1","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113373_bib2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.7326\/0003-4819-125-9-199611010-00003","article-title":"Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. a meta-analysis","volume":"125","author":"Pritchard","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2023.113373_bib3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113373_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2016.07.025","article-title":"Stage III non-small cell lung cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice","volume":"121","author":"Driessen","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2023.113373_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/annonc\/mdn559","article-title":"Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study","volume":"20","author":"De Ruysscher","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113373_bib6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cllc.2014.02.003","article-title":"Stage III non-small-cell lung cancer: establishing a benchmark for the proportion of patients suitable for radical treatment","volume":"15","author":"Al-Shamsi","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2023.113373_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1278-3218(00)88254-2","article-title":"[Radiotherapy for stage III, inoperable, asymptomatic small cell lung cancer. Final results of a prospective randomized study (240 patients)]","volume":"3","author":"Reinfuss","year":"1999","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ejca.2023.113373_bib8","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113373_bib9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113373_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920927841","article-title":"Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study","volume":"12","author":"Yamada","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2023.113373_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(12)70139-0","article-title":"Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)","volume":"13","author":"Atagi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113373_bib12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.113373_bib13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113373_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable Stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.113373_bib15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113373_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cllc.2018.09.012","article-title":"Immune microenvironment differences between squamous and non-squamous non-small-cell lung cancer and their influence on the prognosis","volume":"20","author":"Meng","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2023.113373_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2022.02.014","article-title":"Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations","volume":"167","author":"Riudavets","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113373_bib18","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","article-title":"Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for Stage III non-small cell lung cancer: a systematic review and meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113373_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2021.08.019","article-title":"Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005\/CRIMSON)","volume":"161","author":"Saito","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2023.113373_bib20","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.2217\/fon-2021-0952","article-title":"DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy","volume":"17","author":"Filippi","year":"2021","journal-title":"Future Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923006755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:22Z","timestamp":1760733682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923006755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":20,"alternative-id":["S0959804923006755"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113373","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113373"}}